Context Therapeutics Inc. (CNTX)
CNTX moved a median of -0.22% 30 minutes after news, and -0.87% by the close. How CNTX actually reacts to news — the realized, point-in-time move the market made, measured across 198 labeled events over the last three years with zero look-ahead.
CNTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.65% | 32% | 187 |
| 30-min | -0.22% | 41% | 197 |
| 60-min | -0.50% | 41% | 198 |
| to close | -0.87% | 34% | 198 |
| Middle 50% of CNTX reactions | -2.21% to +1.61% |
|---|---|
| Median reaction (30-min) | -0.22% |
| Measured reactions | 198 |
Half of all Context Therapeutics Inc. news events land between -2.21% and +1.61% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CNTX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 13 | +2.63% | 69% | -2.63% |
| Coverage initiations | 24 | 0.00% | 42% | +1.70% |
| Rating reiterations | 40 | -0.58% | 40% | -0.80% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CNTX ranks against every other measured name →
That’s how CNTX usually reacts — get an email when it moves on news →Email me when CNTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CNTX's baseline. Nothing else.
Recent CNTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 | Press release | GlobeNewswire | -1.65% | -1.67% | |
| Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress | Press release | GlobeNewswire | +4.42% | -0.20% | |
| Form 10-Q Context Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.42% | -0.20% | |
| Form 8-K Context Therapeutics For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +4.42% | -0.20% | |
| Form 8-K Context Therapeutics For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -2.41% | -2.49% | |
| Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.00% | -5.49% | |
| Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes | Press release | GlobeNewswire | -1.17% | +9.38% | |
| Form 8-K Context Therapeutics For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -2.03% | -0.81% | |
| Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 | Press release | GlobeNewswire | -26.15% | -47.76% | |
| Form 8-K Context Therapeutics For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | -26.15% | -47.76% | |
| Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.33% | -3.33% | |
| Context Therapeutics to Present at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +3.53% | +12.88% | |
| Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | Press release | GlobeNewswire | +0.65% | -0.92% | |
| Form 8-K Context Therapeutics For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | -0.92% | |
| Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | Press release | GlobeNewswire | -2.09% | -2.51% | |
| Form 10-Q Context Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.09% | -2.51% | |
| Form 8-K Context Therapeutics For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | +3.52% | +1.32% | |
| Form ARS Context Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -2.79% | -6.77% | |
| Form DEF 14A Context Therapeutics For: Apr 28 | SEC filing · Form DEF | SEC EDGAR | -2.79% | -6.77% | |
| Form DEFA14A Context Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | -2.79% | -6.77% | |
| Form PRE 14A Context Therapeutics For: Jun 24 | SEC filing · Form PRE | SEC EDGAR | -1.65% | -7.00% | |
| Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer | Press release | GlobeNewswire | +1.92% | +4.62% | |
| Form 8-K Context Therapeutics For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +1.92% | +4.62% | |
| Context Therapeutics Reports Full Year 2025 Operating and Financial Results | Press release | GlobeNewswire | -4.88% | -3.05% | |
| Form 10-K Context Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.88% | -3.05% | |
| Form 8-K Context Therapeutics For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | -4.88% | -3.05% | |
| Form S-8 Context Therapeutics | SEC filing · Form S-8 | SEC EDGAR | -4.88% | -3.05% | |
| Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 | Press release | GlobeNewswire | -1.10% | +3.46% | |
| Form 8-K Context Therapeutics For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +5.12% | -7.83% | |
| Form 8-K Context Therapeutics For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +2.83% | +4.09% | |
| Context Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.55% | -3.98% | |
| Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.06% | +9.22% | |
| Form 8-K Context Therapeutics For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -1.77% | -5.33% | |
| Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting | Press release | GlobeNewswire | +0.33% | +4.67% | |
| Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results | Press release | GlobeNewswire | -1.35% | -3.60% | |
| Form 10-Q Context Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.35% | -3.60% | |
| Form 8-K Context Therapeutics For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | -1.35% | -3.60% | |
| Context Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.60% | -6.40% | |
| Form 8-K Context Therapeutics For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | -0.80% | -1.60% | |
| Form 8-K Context Therapeutics For: Oct 17 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | -6.62% | |
| Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting | Press release | GlobeNewswire | -2.59% | +4.31% | |
| Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.59% | +4.31% | |
| Form 8-K Context Therapeutics For: Aug 28 | SEC filing · Form 8-K | SEC EDGAR | +3.53% | -0.02% | |
| Context Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.76% | -4.97% | |
| Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results | Press release | GlobeNewswire | -0.65% | -0.80% | |
| Form 10-Q Context Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.65% | -0.80% | |
| Form 8-K Context Therapeutics For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | -1.24% | +0.11% | |
| Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting | Press release | GlobeNewswire | -3.32% | -2.00% | |
| Form 8-K Context Therapeutics For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -3.32% | -2.00% | |
| Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer | Press release | GlobeNewswire | +9.23% | -5.05% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CNTX section they belong to.
Where else CNTX is measured.
CNTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Context Therapeutics Inc.'s median reaction calculated?
Every labeled CNTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 198 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of CNTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CNTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.